Gross Profit Comparison: Ascendis Pharma A/S and Perrigo Company plc Trends

Pharma Giants' Profit Trends: A Decade of Change

__timestampAscendis Pharma A/SPerrigo Company plc
Wednesday, January 1, 2014139830001447700000
Thursday, January 1, 201581180001712400000
Friday, January 1, 201646060002051800000
Sunday, January 1, 201715300001979500000
Monday, January 1, 2018105810001831500000
Tuesday, January 1, 2019133750001773300000
Wednesday, January 1, 202069530001815200000
Friday, January 1, 202142550001416200000
Saturday, January 1, 2022390370001455400000
Sunday, January 1, 20232223230001680400000
Monday, January 1, 2024319383000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: Ascendis Pharma A/S vs. Perrigo Company plc

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial for investors and stakeholders. This analysis highlights the gross profit trajectories of Ascendis Pharma A/S and Perrigo Company plc from 2014 to 2023. Ascendis Pharma, a Danish biopharmaceutical company, has shown a remarkable growth in gross profit, skyrocketing by over 1,500% from 2014 to 2023. This surge is indicative of its strategic advancements and successful product launches. In contrast, Perrigo Company plc, a global leader in over-the-counter healthcare products, maintained a steady gross profit, peaking in 2016 with a 20% increase from 2014. However, it faced a slight decline in subsequent years, reflecting market challenges and competitive pressures. This comparative analysis underscores the dynamic nature of the pharmaceutical sector, where innovation and market adaptation are key to financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025